ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

41.40
0.00
(0.00%)
Closed December 10 4:00PM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
41.40
Bid
41.00
Ask
41.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
150
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.2-9.2105263157945.645.639.650741.91558185DE
4-6.8-14.107883817448.248.239.617842.85404101DE
12-3.8-8.4070796460245.251.539.615046.14471602DE
26-7.6-15.51020408164957.539.616948.03577184DE
5219.488.18181818182258.521.39999917944.24911102DE
15617.673.949579831923.858.51917141.97393714DE
26017.673.949579831923.858.51917141.97393714DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
013CJDcom Inc
19.55 €
(0.00%)
0
013AJD.com Inc
39.15 €
(0.00%)
0
0110Thesis Gold Inc
0.445 €
(0.00%)
0
00WAspermont Ltd
0.0035 €
(0.00%)
0
000Greenvolt Energias Renovaveis SA
0.00 €
(0.00%)
0
013CJDcom Inc
19.55 €
(0.00%)
0
013AJD.com Inc
39.15 €
(0.00%)
0
0110Thesis Gold Inc
0.445 €
(0.00%)
0
00WAspermont Ltd
0.0035 €
(0.00%)
0
000Greenvolt Energias Renovaveis SA
0.00 €
(0.00%)
0
013CJDcom Inc
19.55 €
(0.00%)
0
013AJD.com Inc
39.15 €
(0.00%)
0
0110Thesis Gold Inc
0.445 €
(0.00%)
0
00WAspermont Ltd
0.0035 €
(0.00%)
0
000Greenvolt Energias Renovaveis SA
0.00 €
(0.00%)
0

Discussion

View Full Feed
boston127 boston127 2 minutes ago
With pre-market at .0047 X .0048,

This will hit into the 5s later on, and probably break .0060. Believe it will close above .0050, between .0052 and .0055. Really liking BMNR also.
BMNR
PioneerPhoenix73 PioneerPhoenix73 3 minutes ago
Silicon Nitride has zero potential uses including curing Mysterious flu-like diseases in Congo. Most of what Boston posts are not examples of actual use cases and are non existent If that "breakthrough" wasn't made up, as well as their imaginary applications and potential total addressable markets,
SINT
gdl gdl 5 minutes ago
Fox News analyst blasts Trump’s ‘rage rhetoric’ comments on jailing J6 committee members

A first. It might be HIS last time with FOX. I guess fascism isn't acceptable YET by FOX propaganda machine yet. It will be.

If FOX announcers start to panic, what do you think wi
gitreal gitreal 5 minutes ago
I don't think there will be, I seriously doubt there are any PGMs. If there were, they'd have proudly released the proof in the form of an actual third party report....and this stock would be trading in the dollars.

If an assay report is issued, it will be from some specialty lab
SDRC
mrfence mrfence 6 minutes ago
Actually, Ralph Nadar's letter ran us to about $5.50 from a buck back in the day. Imagine the run we'd see if Trump picked the founder of CapWealth that wrote the book, Another Big Lie: How the Government Stole Billions from the American Dream of Home Ownership. and Got Caught!, as the new FHFA Dir
FNMA
Harksg1 Harksg1 14 minutes ago
We too 2024 was very disappointing. Hopefully 2025 will be a good year. Your continuous stream of the same negative messages has no added value and is just annoying and irritating. Stop that and go do something useful!!!
LWLG
Pickme2 Pickme2 21 minutes ago
It's real simple....go read the fillings...if you can't read...not my problem ....don't get conned by the condog 🤡 manipulating scammer!!! 
ATMH
JohnnyHydrogen JohnnyHydrogen 24 minutes ago
The Exxon and CCS deal is very confusing.

I have tried to follow it closely and I am still confused. On the one hand, I can't help but think that Exxon is not very interested and maybe even is going to screw FCEL financially in whatever agreement they have.

On the oth
FCEL
uber darthium uber darthium 25 minutes ago
What happened to “I’ll see you Jan 2 and you were away for the next 30 days” ?

Taking time out of your vacation for a pump to help this falling rock share printing scheme ?
IFUS
nwsun nwsun 26 minutes ago
Don't you wonder why and who is managing the daily trading performance in this stock? I don't like the performance here either but I still think some entity is managing this stock.. Who precipitates the tiny volume we saw today. There has to be a reason? I dont think it's retail trading 30k in tra
SFLM
sam1933 sam1933 29 minutes ago
A 20% flush of altcoins' to flush out overleveraged positions and truly test the bulls' sentiment and resolve.

Let's see whose bulls perform better after the correction:
https://stockcharts.com/freecharts/candleglance.html?$ETHUSD,$XRPUSD,$ALGOUSD,$ADAUSD,$HBARUSD,$XLMUSD,$LINK
ADAUSD ALGOUSD ATOMUSD
XenaLives XenaLives 29 minutes ago
The only real solution - personal Spritual and Cultural integrity.

Now - if one were to remove cultural and religious references in this post, I believe it would be humanity's ultimate Spiritual "emancipation proclimation:......

https://en.wikipedia.org/wiki/Second_
Chiugray Chiugray 30 minutes ago
Whether you know it or not, you are making my point, that Retail get the major gains if they hold onto shares and do not sell early. With a great investment, it is about "knowing when to hold them". It is about not falling for FUD and being tricked into selling too soon. And in the rare case of owni
NWBO
nowwhat2 nowwhat2 32 minutes ago
Gray-headedness is a crown of beauty when it is found in the way of righteousness


https://investorshub.advfn.com/uimage/uploads/2024/12/10/hvtpqTWAIN_QUESTION.jpg



NAILED it.



.
XRPUSD
rickstereo3333 rickstereo3333 34 minutes ago
Was there ever any discussion about how long said Radiogel trials would take?

Whether all Phases 1-3 would have to be completed?
RDGL
XenaLives XenaLives 34 minutes ago
Thanks, sounds intersting...

I hve had the mindset of an anthropologist and an understanding of psychology since the '60's

IMO the two schools of science can not be understood independently.
XenaLives XenaLives 34 minutes ago
Thanks, sounds intersting...

I hve had the mindset of an anthropologist and an understanding of psychology since the '60's

IMO the two schools of science can not be understood independently.
konshe konshe 35 minutes ago
News is good, PPS will be rebound soon.
TPTW
Alan Brown Alan Brown 35 minutes ago
The US equivalent of the Chinese PDD?
PDD
Truthsocial Truthsocial 38 minutes ago
For all the FDA cheerleaders where is the FDA on this subject delaying delaying the inevitable that the facts show its a biological weapon....whereas we know for a fact RDGL works outpatient minimal side affects with minimal big Pharma medicine....

https://www.fda.gov/safety/industry-
RDGL
gfp927z gfp927z 38 minutes ago
Xena, You might want to check out author Joseph Atwill's info for a real mind-blower. He is best known for his book 'Caesar's Messiah', but his more recent research explores the astonishing connections between the rise of Nazism and Zionism, and how they came from the same source. It's a shocker,
wsidejack wsidejack 39 minutes ago
Agreed.

But some days he brought his own lunch, so he knows what Apple is. 😁
CrimsonNightRider CrimsonNightRider 39 minutes ago
Eminent Crash

https://investorshub.advfn.com/uimage/uploads/2024/3/8/zkojbIMG_7314.jpeg
IQST
CrimsonNightRider CrimsonNightRider 41 minutes ago
Scam maybe?

https://investorshub.advfn.com/uimage/uploads/2024/11/21/zziuwIMG_2735.jpeg
IQST
Scotchie8888 Scotchie8888 42 minutes ago
Hello. I’m trying to purchase this on Robinhood and I can’t find the calls … please help.. thnx

Your Recent History

Delayed Upgrade Clock